Current Issue

December 2024

Superhero and Villain

Although shows like Supacell bring awareness to sickle cell disease, many media depictions contribute to stereotypes and misinformation.

Viewpoints

Editor’s Corner

A Thousand Milestones to Move Us Forward

Book Reviews

Toxic Exposure: Into the Weeds of the Monsanto Trials

Education

You Make the Call

You Make the Call: How would you treat progressive classical Hodgkin lymphoma in a patient who has received multiple lines of therapy?

You Make the Call Readers' Response

How would you treat progressive classical Hodgkin lymphoma in a patient who has received multiple lines of therapy?

Spotlight

Feature Articles

Superhero and Villain

Pulling Back the Curtain

Pulling Back the Curtain: Belinda R. Avalos, MD

Drawing First Blood

Drawing First Blood: How Long Should Patients With a Myeloproliferative Neoplasm Be Anticoagulated?

News

In a Different Vein: News from the Blood Journals

New Therapy May Be Effective for Patients With Cold Agglutinin Disease, Warm Antibody Autoimmune Hemolytic Anemia

ASH Directions

Judith Kleinerman Receives ASH Exemplary Service Award
ASH Elects Four New Leaders to the Executive Committee

Decade in Review

ASH Clinical News: A Decade in Review

Data Stream

December 2024 Data Stream

Online Exclusives

In a Different Vein: News from the Blood Journals

Soluble Anti-B-Cell Maturation Antigen, High Disease Burden Modulate Responses in Patients With MM Receiving BCMA T-Cell–Engager Therapy
Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib
Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose
BOVen Regimen NCCN-Approved Option for TP53-Mutated MCL
ASH Recruitment Program Boosts Representation in Hematology Field, Study Shows

Literature Scan

MGUS Risk Assessment Over Time Yields Benefits, Study Shows
Lactated Ringer Preferred Over Normal Saline in SCD Vaso-Occlusive Episodes
Significant Proportion of Cancer Trials Exclude Individuals with Duffy Null–Associated Neutrophil Count, Study Finds
Discontinuing Maintenance Therapy for Multiple Myeloma Is Feasible, New Study Shows
New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML
More Work Needed to Overcome Racial, Ethnic AHCT Disparities in Multiple Myeloma